CymaBay Therapeutics, Inc.: insider trades · United States · SEC (Form 4)

About CymaBay Therapeutics, Inc.

CymaBay Therapeutics, Inc. was a U.S. biopharmaceutical company focused on therapies for liver and inflammatory diseases, with its strategic identity increasingly centered on primary biliary cholangitis (PBC). The company was founded in 1988 and was headquartered in Newark, California, United States. It traded on the NASDAQ under the ticker CBAY before being acquired by Gilead Sciences in March 2024. For investors, that distinction matters: CymaBay is no longer an independent NYSE/NASDAQ-listed equity, but its clinical assets and development track record remain relevant in assessing the strategic rationale behind the acquisition. ([gilead.com](https://www.gilead.com/news/news-details/2024/gilead-sciences-expands-liver-portfolio-with-acquisition-of-cymabay-therapeutics?utm_source=openai)) CymaBay’s lead program was seladelpar, a PPARδ agonist developed for PBC, a rare chronic liver disease with significant unmet medical need. The company built its value proposition around advancing seladelpar through Phase 2 and Phase 3 studies and securing supportive regulatory designations, including FDA Breakthrough Therapy designation and EMA PRIME status for certain patient populations. In practical terms, CymaBay operated as a focused biotech rather than a diversified platform company: its upside depended heavily on clinical efficacy, safety, and regulatory execution for a single core asset. That structure made the stock highly event-driven, with valuation often driven by trial readouts and filing milestones rather than broad operating fundamentals. ([gilead.com](https://www.gilead.com/news/news-details/2024/gilead-sciences-expands-liver-portfolio-with-acquisition-of-cymabay-therapeutics?utm_source=openai)) From a competitive standpoint, CymaBay occupied a specialized position within the liver-disease therapeutics market. Its differentiation came from the depth of seladelpar data, including a profile that Gilead described as aligned with its long-standing liver-disease franchise. The acquisition announcement valued CymaBay at $32.50 per share in cash, or about $4.3 billion in equity value, underscoring how a single late-stage asset in a niche therapeutic area can attract strategic interest from a global pharmaceutical acquirer. ([gilead.com](https://www.gilead.com/news/news-details/2024/gilead-sciences-expands-liver-portfolio-with-acquisition-of-cymabay-therapeutics?utm_source=openai)) The most important recent development is the completion of Gilead’s acquisition in March 2024. Since then, seladelpar has been folded into Gilead’s liver portfolio, and CymaBay’s standalone equity story has effectively ended. For French, Belgian, and Swiss investors studying U.S. healthcare listings on the NASDAQ, CymaBay is a useful example of a capital-efficient biotech built around a lead asset, advanced through late-stage development, and ultimately monetized through M&A rather than a long period of post-launch commercialization. ([investors.gilead.com](https://investors.gilead.com/news/news-details/2024/Gilead-Sciences-Announces-Completion-of-Acquisition-of-CymaBay/default.aspx?utm_source=openai))